|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2007-9-5
|
|
pubmed:abstractText |
Five patients with relapsed PCNSL were given chemo-immunotherapy (rituximab followed by carboplatin and methotrexate) with osmotic blood-brain barrier (BBB) opening. Four patients achieved CR and one patient had stable disease. Two patients (2/5) had durable responses (survival: 230+, 122+, 82, 42, 38 weeks). One patient later received Indium-111-ibritumomab tiuxetan and Yttrium-90-ibritumomab tiuxetan intravenous, without BBB opening. There was good uptake of Indium-111 ibritumomab tiuxetan in tumor on SPECT scan after 48 h. Estimated radiation doses to brain around and distant from tumor were within safe limits. After Ytrium-90 ibritumomab tiuxetan there was CR in enhancing tumor where the BBB was leaky, but lesions occurred in other brain regions, where the BBB was intact during Yttrium-90 ibritumomab tiuxetan infusion. Imaging and dosimetry with Indium-111 ibritumomab tiuxetan and efficacy with Yttrium-90 ibritumomab tiuxetan suggest the need for future enhanced CNS delivery when using monoclonal or radiolabeled antibodies, as intravenous delivery alone may provide modest clinical benefit due to limited BBB permeability.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1042-8194
|
|
pubmed:author |
pubmed-author:BelangerRichardR,
pubmed-author:DoolittleNancy DND,
pubmed-author:HaluskaMarianneM,
pubmed-author:HedrickNancy ANA,
pubmed-author:JahnkeKristophK,
pubmed-author:LacyCynthia ACA,
pubmed-author:NanceRobert WRWJr,
pubmed-author:NeuweltEdward AEA,
pubmed-author:RyanDeborah ADA,
pubmed-author:TysonRose MarieRM,
pubmed-author:VarallyayCsanadC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1712-20
|
|
pubmed:dateRevised |
2007-12-3
|
|
pubmed:meshHeading |
pubmed-meshheading:17786706-Adult,
pubmed-meshheading:17786706-Aged,
pubmed-meshheading:17786706-Antibodies, Monoclonal,
pubmed-meshheading:17786706-Blood-Brain Barrier,
pubmed-meshheading:17786706-Brain Neoplasms,
pubmed-meshheading:17786706-Carboplatin,
pubmed-meshheading:17786706-Combined Modality Therapy,
pubmed-meshheading:17786706-Female,
pubmed-meshheading:17786706-Humans,
pubmed-meshheading:17786706-Indium Radioisotopes,
pubmed-meshheading:17786706-Lymphoma, Non-Hodgkin,
pubmed-meshheading:17786706-Male,
pubmed-meshheading:17786706-Methotrexate,
pubmed-meshheading:17786706-Middle Aged,
pubmed-meshheading:17786706-Radioimmunotherapy,
pubmed-meshheading:17786706-Yttrium Radioisotopes
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.
|
|
pubmed:affiliation |
Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, N.I.H., Extramural
|
